Drug intelligence / Profile preview

GW805858

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules
Administration: Inhalation

Overview

GW805858 is a small molecule drug that was developed by GSK for the treatment of immune system and respiratory diseases, with a primary focus on asthma. The compound advanced to phase 1 clinical trials, where it was evaluated for safety and tolerability in both healthy volunteers and individuals with mild asthma. Development of GW805858 has since been discontinued, and there are no active indications or ongoing clinical development reported. Detailed information about its mechanism of action or molecular target has not been disclosed in public sources[1][2][3].

Other names: GW-805858GW805858GW 805858

Targets

CCR1

Beyond the preview

Go deeper on GW805858.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW805858.

Explore the full profile